Jeil Health Sciences achieved 18% growth compared to last year
Cheil Pharma Holdings (CEO Sang-cheol Han) and Cheil Pharmaceutical (CEO Seong Seok-je) hold the 61st and 4th regular shareholders’ meetings in sequence at the headquarters auditorium starting at 9 am on March 23rd, and 14% cash each. The dividend has been decided.
On the day, Seong Seok-je, president of Jeil Pharmaceutical said, “The unprecedented new virus called’Corona 19′, which is still persisting, causes changes in daily life around the world and the resulting long-term economic downturn. Changes in the field are aggravated by difficulties that are difficult to handle, such as facing various challenges across the industry, but the unchanging support of shareholders sent last year and the dedication of all executives and staff members made it possible to achieve a growth rate of 3% compared to the previous year. He was the driving force.”
Next, among the meaningful achievements achieved last year, global clinical preparation of’double target anticancer drug JPI-547′ and’reflux esophagitis treatment JP-1366′ of’Onconic Therapeutics’, a new drug development company established in May last year in the R&D field, In addition, the representative new drug’JPI-289 stroke treatment phase 2A phase cohort 3’and diabetes drug’JP-2266′ in Europe phase 1 clinically progressed smoothly. Said it would.
Han Sang-cheol, president of Cheil Pharma Holdings, said that he wants to prepare for the future by laying the foundation for a 100-year company as the number one holding company. As mentioned above, large-scale facility investment was made to remodel the patch production facility and introduce new facilities, and by completing the new factory and producing products in earnest in the second half of this year, the status of the famous patch price in the domestic and export markets will be raised to the next level, and Through Onconic Therapeutics, a company specializing in new drug research and development, Jeil Pharm will secure investment in new drug development and enable smooth global clinical advancement, thereby enhancing the value of Jeil Pharm’s new drug and permitting innovative new drugs that lead globally. And he emphasized that it will further accelerate the release.
Meanwhile, the appointment of Cheil Pharma Holdings’ outside directors and audit committee members as outside directors, and the appointment of outside directors to become audit committee members were resolved as follows.
<제일파마홀딩스>
Appointment of outside directors and audit committee members as outside directors
: Kibong Park (Former, Director of Yangjaenam Financial Center, KB Kookmin Bank/ Former Head of Gangnam 1 Regional Headquarters, KB Kookmin Bank)
Appointment of outside director to become audit committee
: Dong-Yeul Lee (Former, Head of Corporate Sales Division, Lotte Insurance / Currently, STM-NET General Manager)[팜뉴스=최선재 기자]
Copyright © Farm News Unauthorized reproduction and redistribution prohibited